P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Death Pathways

Background:

• Multidrug resistance (MDR) is a major challenge in cancer chemotherapy, often caused by P-glycoprotein overexpression.
• P-glycoprotein is known to efflux drugs but may also have a broader role in preventing cell death.

Purpose of the Study:

• To investigate the potential antiapoptotic function of P-glycoprotein beyond drug efflux.
• To determine if P-glycoprotein confers resistance to various death stimuli and if this resistance can be reversed.

Main Methods:

• Cells were engineered to express P-glycoprotein via drug selection or retroviral transduction.
• Resistance to caspase-dependent (FasL, TNF, UV) and caspase-independent (pore-forming proteins, granzyme B) death stimuli was assessed.
• The effect of anti-P-glycoprotein antibodies and verapamil on apoptosis was evaluated.
• Clonogenic assays were used to assess long-term cell survival.

Main Results:

• P-glycoprotein expression conferred resistance to multiple caspase-dependent apoptotic stimuli.
• Cells expressing P-glycoprotein remained sensitive to caspase-independent cell death.
• Inhibition of P-glycoprotein function with antibodies or verapamil restored sensitivity to caspase-dependent apoptosis.
• P-glycoprotein conferred long-term resistance to caspase-dependent stimuli but not caspase-independent ones.

Conclusions:

• P-glycoprotein possesses a significant antiapoptotic function, protecting cells from diverse death signals.
• Targeting P-glycoprotein may be a viable strategy to overcome MDR and enhance cancer therapy efficacy.
• Further research is needed to elucidate the precise molecular mechanisms by which P-glycoprotein inhibits caspase-dependent cell death.